Project Code: HL04

Project Name: Bevacizumab Injection

Bevacizumab Injection

Product Name: Anbeiyou

Formerly known as: Recombinant Anti VEGF Monoclonal Antibody Injection

Target: VEGF

Indications under study: metastatic colorectal cancer; Advanced, metastatic, or recurrent non-small cell lung cancer; Recurrent glioblastoma; Hepatocellular carcinoma; Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; cervical cancer

Dosage form: Injection

Administration method: intravenous injection

Specification: 100 mg/4 mL

Original research product: Bevacizumab, Avastin

Progress: Listed (November 15, 2024)

Belonging company: Hualan Ankang Biotechnology Co., Ltd